Biopharmaceuticals / Monoclonal Antibody Development
Strategic Profile
The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. CASI is transitioning toward clinical-stage focus on CID-103, a potentially best-in-class anti-CD38 candidate with significant unmet medical need in transplant rejection and immunological indications, positioning it at an inflection point in its product development.
Cyborg Score Rationale
CASI shows promise with a lead candidate (CID-103) in active development and analyst support (Strong Buy rating with $4.0 price target), but faces operational challenges including stock delisting concerns, minimal current revenues from early-stage programs, and a small employee base. The clinical-stage nature with limited commercialized products creates execution risk.
Top Insights
Analyst rating is "Strong Buy" with a 12-month stock price target of $4.0
Company is focused almost entirely on CID-103 anti-CD38 development with clinical trials planned in renal allograft antibody-mediated rejection
As of January 18, 2026, the company has 233 employees, indicating early-stage operational scale
Limited commercialization of existing products (EVOMELA, legacy assets) with focus shifting to new anti-CD38 therapeutic
Named Competitors
Daratumumab — Approved anti-CD38 for multiple myeloma and other hematologic malignancies
Isatuximab — Approved anti-CD38 for multiple myeloma
Other clinical-stage anti-CD38 programs — Emerging competitors in immunological and transplant indications
Recent Developments
(December 2025) Additional proof-of-concept data for CID-103 shared at ASH 2025
(November 2025) James Huang appointed as Non-Executive Chairman of CASI Board of Directors
(August 2025) Clinical-stage focus reinforced with ongoing development of therapeutic pipeline
Open the full interactive CASI Pharmaceuticals report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.